Novolog (Pharm-Up 1966) Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Eran Taus

Chief Executive Officer (CEO)

₪3.2m

Compensación total

Porcentaje del salario del CEO	62.7%
Permanencia del CEO	6.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	6.7yrs

Actualizaciones recientes de la dirección

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

Dec 29

Recent updates

Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)

Nov 05

Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital

Jul 25

I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease

May 07

Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend

Apr 14

Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality

Mar 24

Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 09

How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?

Feb 15

Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years

Jan 25

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

Dec 29

With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting

Dec 08

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Eran Taus en comparación con los beneficios de Novolog (Pharm-Up 1966)?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-₪42m
Sep 30 2023	n/a	n/a	₪16m
Jun 30 2023	n/a	n/a	₪26m
Mar 31 2023	n/a	n/a	₪26m
Dec 31 2022	₪3m	₪2m	₪48m
Sep 30 2022	n/a	n/a	₪43m
Jun 30 2022	n/a	n/a	₪43m
Mar 31 2022	n/a	n/a	₪41m
Dec 31 2021	₪4m	₪2m	₪42m
Sep 30 2021	n/a	n/a	₪41m
Jun 30 2021	n/a	n/a	₪40m
Mar 31 2021	n/a	n/a	₪40m
Dec 31 2020	₪4m	₪2m	₪40m
Sep 30 2020	n/a	n/a	₪38m
Jun 30 2020	n/a	n/a	₪24m
Mar 31 2020	n/a	n/a	₪18m
Dec 31 2019	₪3m	₪2m	₪10m
Sep 30 2019	n/a	n/a	₪9m
Jun 30 2019	n/a	n/a	₪18m
Mar 31 2019	n/a	n/a	₪22m
Dec 31 2018	₪3m	₪2m	₪23m

Compensación vs. Mercado: La compensación total de Eran($USD835.07K) está por encima de la media de empresas de tamaño similar en el mercado IL ($USD636.10K).

Compensación vs. Ingresos: La compensación de Eran ha sido consistente con los resultados de la empresa en el último año.

CEO

Eran Taus (59 yo)

6.8yrs

Permanencia

₪3,170,000

Compensación

Mr. Eran Taus has been the Chief Executive Officer of Novolog (Pharm-Up 1966) Ltd. since August 2017. Mr. Taus served as the Chief Executive Officer of Chemovil Ltd.Mr. Taus served as the Chief Executive...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eran Taus	Chief Executive Officer	6.8yrs	₪3.17m	sin datos
Amir Shachar	Chief Financial Officer	3.8yrs	₪1.94m	sin datos
Eli Dahan	Advisor to CEO	no data	₪193.00k	sin datos
Nega Hon	Vice President of Information Systems	1.4yrs	sin datos	sin datos
Adi Marx	Vice President of Business Development & Special Projects	1.3yrs	sin datos	sin datos
Tali Avigdor	Vice President of Human Resources & Integration	1.2yrs	sin datos	sin datos
Assi Weshler	Chief Executive Officer of Trilog & Medicare to Home	no data	sin datos	sin datos
Yehiel Asia	Chief Executive Officer of Ein Tal	no data	sin datos	sin datos
David Shmuelov	Chief Executive Officer of Drug Distribution & Medical Device Company	5yrs	sin datos	sin datos
Rafi Friedman	Chief Executive Officer of Mediplast Israel Ltd.	6.3yrs	₪1.32m	sin datos
Amitai Gridish	Chief Executive Officer of Target Care Services Ltd.	5yrs	sin datos	sin datos
Ofer Amar	Chief Executive Officer of Mediquip Ltd.	6.6yrs	₪2.03m	sin datos

5.0yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NVLG es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Tamar Gottlieb	Independent Non-Executive Director	1.5yrs	sin datos	sin datos
David Ben-Ami	Independent External Director	7yrs	sin datos	sin datos
Miriam Shave	Independent External Director	7yrs	sin datos	sin datos
Itay Taleh	Director	7.8yrs	sin datos	sin datos
Demi Dor	Chairman of the Board	6.4yrs	₪480.00k	sin datos
Varda Shalev	Director	1.4yrs	sin datos	sin datos

6.7yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de NVLG se considera experimentada (6.9 años de antigüedad promedio).

Novolog (Pharm-Up 1966) Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Novolog (Pharm-Up 1966) Ltd Appoints Tami Gottlieb as an Independent Non-Executive Director

Insufficient new directors

Insufficient new directors

Insufficient new directors

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

Recent updates

Full year 2023 earnings released: ₪0.082 loss per share (vs ₪0.094 profit in FY 2022)

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: ₪0.001 (vs ₪0.02 in 3Q 2022)

Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: ₪0.023 (vs ₪0.024 in 2Q 2022)

Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital

First quarter 2023 earnings released: ₪0.02 loss per share (vs ₪0.024 profit in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: ₪0.094 (vs ₪0.084 in FY 2021)

Investor sentiment deteriorates as stock falls 17%

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2022 Results on Mar 20, 2023

Investor sentiment deteriorates as stock falls 15%

Novolog (Pharm-Up 1966) Ltd Appoints Tami Gottlieb as an Independent Non-Executive Director

Third quarter 2022 earnings released: EPS: ₪0.02 (vs ₪0.02 in 3Q 2021)

Insufficient new directors

Novolog (Pharm-Up 1966) Ltd to Report Q3, 2022 Results on Nov 16, 2022

Second quarter 2022 earnings released: EPS: ₪0.024 (vs ₪0.02 in 2Q 2021)

Insufficient new directors

Novolog (Pharm-Up 1966) Ltd to Report Q2, 2022 Results on Aug 10, 2022

Insufficient new directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Novolog (Pharm-Up 1966) Ltd to Report Q1, 2022 Results on May 18, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2021 Results on Mar 14, 2022

Third quarter 2021 earnings released: EPS ₪0.022 (vs ₪0.021 in 3Q 2020)

I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease

Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend

Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality

Upcoming dividend of ₪0.032 per share

Full year 2020 earnings released: EPS ₪0.086 (vs ₪0.026 in FY 2019)

Novolog (Pharm-Up 1966) Ltd to Report Fiscal Year 2020 Results on Mar 17, 2021

Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?

New 90-day low: ₪2.76

Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years

Novolog (Pharm-Up 1966) Ltd announced that it has received ILS 119.999999 million in funding

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting

Third quarter 2020 earnings released: EPS ₪0.021

Market bids up stock over the past week

New 90-day high: ₪3.20

New 90-day high - ₪3.09

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad